BR112015025748A2 - construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna - Google Patents

construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna

Info

Publication number
BR112015025748A2
BR112015025748A2 BR112015025748A BR112015025748A BR112015025748A2 BR 112015025748 A2 BR112015025748 A2 BR 112015025748A2 BR 112015025748 A BR112015025748 A BR 112015025748A BR 112015025748 A BR112015025748 A BR 112015025748A BR 112015025748 A2 BR112015025748 A2 BR 112015025748A2
Authority
BR
Brazil
Prior art keywords
dna construction
immunomodulation
vaccine
pharmaceutical composition
dna construct
Prior art date
Application number
BR112015025748A
Other languages
English (en)
Inventor
Wittig Burghardt
Kleuss Christiane
Kapp Kerstin
Schroff Matthias
Original Assignee
Mologen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen Ag filed Critical Mologen Ag
Publication of BR112015025748A2 publication Critical patent/BR112015025748A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna a presente invenção se refere a um construto de dna covalentemente fechado, uma composição farmacêutica e uma vacina e seu uso para a modulação do sistema imunológico. fornece um construto de dna para imunomodulação que compreende uma sequência de dna específica. 1/1
BR112015025748A 2014-02-18 2015-02-18 construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna BR112015025748A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1402847.6A GB2523187A (en) 2014-02-18 2014-02-18 Covalently closed non-coding immunomodulatory DNA construct
PCT/EP2015/053396 WO2015124614A1 (en) 2014-02-18 2015-02-18 Covalently closed non-coding immunomodulatory dna construct

Publications (1)

Publication Number Publication Date
BR112015025748A2 true BR112015025748A2 (pt) 2017-10-10

Family

ID=50440342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025748A BR112015025748A2 (pt) 2014-02-18 2015-02-18 construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna

Country Status (16)

Country Link
US (1) US10280424B2 (pt)
EP (1) EP2999787B1 (pt)
JP (1) JP6067893B2 (pt)
KR (1) KR101831713B1 (pt)
CN (1) CN105264074A (pt)
AU (1) AU2015220911B2 (pt)
BR (1) BR112015025748A2 (pt)
CA (1) CA2908522A1 (pt)
DK (1) DK2999787T3 (pt)
ES (1) ES2634002T3 (pt)
GB (1) GB2523187A (pt)
HK (1) HK1216758A1 (pt)
MX (1) MX2015014190A (pt)
RU (1) RU2668387C2 (pt)
SG (1) SG11201508108YA (pt)
WO (1) WO2015124614A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN107106493A (zh) 2014-11-21 2017-08-29 西北大学 球形核酸纳米颗粒缀合物的序列特异性细胞摄取
LU92821B1 (en) * 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) * 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
SG11202001709WA (en) 2017-08-31 2020-03-30 Mologen Ag Tlr-9 agonists for modulation of tumor microenvironment
KR20220133999A (ko) * 2020-01-31 2022-10-05 타이리스 테라뷰틱스, 에스.엘. 변형된 뉴클레오티드들을 갖는 닫힌 선형 dna

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
AU2003277865B2 (en) * 2002-06-25 2008-08-21 City Of Hope Adjuvant-free peptide vaccine
ZA200507063B (en) * 2003-03-26 2007-03-28 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use
EP1728863A3 (en) 2003-10-30 2006-12-20 Coley Pharmaceutical GmbH C-class oligonucleotide analogs with enhanced immunostimulatory potency
DK1699480T3 (da) * 2003-12-30 2011-10-10 Mologen Ag Allogent terapeutisk tumormiddel
WO2005080567A1 (de) * 2004-02-20 2005-09-01 Mologen Ag Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren
WO2006015560A1 (de) * 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
KR20090012265A (ko) * 2006-05-11 2009-02-02 몰로겐 아게 면역자극용 멀티머
WO2010039137A1 (en) 2008-10-02 2010-04-08 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
EP2246433A1 (de) 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
GB2523187A (en) * 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct

Also Published As

Publication number Publication date
RU2015140720A (ru) 2017-03-29
JP6067893B2 (ja) 2017-01-25
AU2015220911B2 (en) 2017-02-02
GB2523187A (en) 2015-08-19
KR20150130425A (ko) 2015-11-23
SG11201508108YA (en) 2015-10-29
RU2668387C2 (ru) 2018-09-28
EP2999787A1 (en) 2016-03-30
ES2634002T3 (es) 2017-09-26
CA2908522A1 (en) 2015-08-27
DK2999787T3 (en) 2017-08-07
MX2015014190A (es) 2015-12-11
CN105264074A (zh) 2016-01-20
US10280424B2 (en) 2019-05-07
GB201402847D0 (en) 2014-04-02
KR101831713B1 (ko) 2018-02-23
JP2016526373A (ja) 2016-09-05
HK1216758A1 (zh) 2016-12-02
WO2015124614A1 (en) 2015-08-27
EP2999787B1 (en) 2017-04-19
AU2015220911A1 (en) 2015-10-15
US20160348114A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
BR112016024644A2 (pt) vacinas de ácido nucleico
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
BR112017012679A2 (pt) compostos imunomoduladores, seus usos, composição e kit
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112015030582A2 (pt) Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
BR112016022062A2 (pt) Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
CO2019007116A2 (es) Exopolisacáridos y sus usos
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
MX2019004690A (es) Constructos de anticuerpos.
BR112017020178A2 (pt) vacina estreptocócica
CU20170018A7 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
EP3534944A4 (en) COMBINATION OF A LISTERIA-BASED VACCINE WITH ANTI-CTLA-4 OR ANTI-CD137 ANTIBODIES

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2554 DE 17/12/2019.